Latest Breaking News On - Timothy warbington - Page 3 : comparemela.com

Creative Medical Technology Reports IRB Approval for Phase ½ Clinical Trial of Novel Cell Therapy to Treat Type 1 Diabetes

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Company reaches next clinical trial milestone for the intramuscular treatment of Chronic Lower Back Pain with the first novel allogenic cellular therapy in the United States PHOENIX, Oct. 10, 2023.

Creative Medical Technology Holdings gets green light for StemSpine trial

Creative Medical Technology Holdings got FDA clearance for its Phase 1/2 clinical trial for its StemSpine procedure using AlloStem, according to a Sept. 19 news release.

Creative Medical Technology Holdings (CELZ) Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine using AlloStem

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

/PRNewswire/ Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on.